MedPath

Augmenting Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga Among Older Adults

Not Applicable
Recruiting
Conditions
Anxiety
Benzodiazepine
Insomnia
Deprescription
Interventions
Other: Acupuncture
Other: Yoga
Other: Deprescribing
Registration Number
NCT06197243
Lead Sponsor
Vanderbilt University Medical Center
Brief Summary

The main purpose of this 12-week study is to see if a new combination of treatments can help older adults reduce benzodiazepine or related medication use. The treatment combination consists of 1) medical provider visits to gradually reduce the medication dose over 12 weeks, 2) acupuncture treatments, and 3) private yoga classes. Participants will be offered weekly visits for 12 weeks to receive combined treatments. Participants will be provided surveys before, during, and after the study to learn about their experience of the treatments. At the end of the study, participants will be invited to participate in a focus group to learn about their experience in the study.

Detailed Description

This study consists of a single-arm clinical study among 30 older adults taking benzodiazepine receptor antagonists (BRZA) to assess the feasibility of protocol-driven BRZA deprescribing augmented with combined acupuncture and yoga. Adults 65 years or older that are taking BRZA will be recruited. Deprescribing will be provided at weekly visits with a psychiatric nurse practitioner at the Osher Center for Integrative Health at Vanderbilt University Medical Center. Participants will receive acupuncture and yoga from a staff acupuncturist and yoga instruction from a yoga instructor at the Osher Center. Feasibility of study enrollment will occur through the study enrollment period. Feasibility of study treatments will be evaluated during and after study treatment delivery. Feasibility of study outcome assessments will occur at baseline, 4, 8, and 12 weeks. Throughout the research process, investigators will engage a Stakeholder Advisory Panel consisting of patients and clinicians.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria
  • 65 years and older
  • Taking benzodiazepines or related medications (i.e. zolpidem, zopiclone, eszopiclone, zaleplon) at least 4 times in the last month
  • English speaking
  • Ability to understand study procedures and to comply with them for the length of the study
Read More
Exclusion Criteria
  • Cognitive impairment
  • Drinking more than 3 alcoholic beverages per day
  • Substance abuse disorder
  • Uncontrolled psychiatric disorder, such as major depression or psychosis
  • Inability or unwillingness of individual or legal guardian.representative to give written informed consent.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Feasibility, Adherence and Acceptability MeasureYogaAssay of feasibility of study enrollment and feasibility of study treatments, the latter of which is measured via fidelity, adherence, and acceptability of/to treatments and interventions. Interventions administered for 12 weeks. Fidelity, adherence, and acceptability will be measured via patient survey and engagement.
Feasibility, Adherence and Acceptability MeasureAcupunctureAssay of feasibility of study enrollment and feasibility of study treatments, the latter of which is measured via fidelity, adherence, and acceptability of/to treatments and interventions. Interventions administered for 12 weeks. Fidelity, adherence, and acceptability will be measured via patient survey and engagement.
Feasibility, Adherence and Acceptability MeasureDeprescribingAssay of feasibility of study enrollment and feasibility of study treatments, the latter of which is measured via fidelity, adherence, and acceptability of/to treatments and interventions. Interventions administered for 12 weeks. Fidelity, adherence, and acceptability will be measured via patient survey and engagement.
Primary Outcome Measures
NameTimeMethod
BRZA dose changeBaseline to 12 weeks

Dose of BRZA for patients will be measured at baseline, 4, 8, and 12 weeks

Secondary Outcome Measures
NameTimeMethod
InsomniaBaseline to12 weeks

Will use Patient Reported Outcomes Measurement Information System(PROMIS) Sleep Disturbance Computerized Adaptive Testing to assess difficulties staying and falling asleep. The minimum value is 0 and the maximum value is 100, with higher scores determining worse outcomes.

Proportion of participants whom the investigators collect primary and secondary outcomes.Baseline to 12 weeks

Will estimate feasibility of data collection for study measures by calculating proportion of participants whom the investigators collect primary and secondary outcomes.

AnxietyBaseline to 12 weeks

Will use Patient Reported Outcomes Measurement Information System(PROMIS) Anxiety Computerized Adaptive Testing. The minimum value is 0 and the maximum value is 100, with higher scores determining worse outcomes.

Trial Locations

Locations (1)

Osher Center for Integrative Health at Vanderbilt

🇺🇸

Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath